Eton Pharmaceuticals, Inc. (ETON) Guidance & Earnings Results
On 2026-08-13 Eton Pharmaceuticals, Inc. raised guidance: "FY2026 revenue guidance raised to >$145M from >$120M; Adj. EBITDA margin guidance raised to at least…" — from its own filing, as read by EquiReason.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
ETONEton Pharmaceuticals, Inc.Follow ETON — free
—
Price chart with a free account
- Market cap
- 1.4B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 5 Nov, in 12 days
What management guided
each earnings 8-K · figures checked against the filing text| Release | Direction | What they said |
|---|---|---|
| 13 Aug 26 | Raised | FY2026 revenue guidance raised to >$145M from >$120M; Adj. EBITDA margin guidance raised to at least 35%. · full year |
| 14 May 26 | Raised | Revenue guidance raised from $110M to >$120M for FY2026 · full year |
| 19 Mar 26 | Raised | FY2026 revenue >$110M, Adj EBITDA margin >30% · full year |
| 7 Aug 25 | Raised | Annual revenue run rate ~$80M in Q3 2025, one quarter ahead of prior guidance. · full year |
Eton Pharmaceuticals, Inc. — questions
- What guidance did Eton Pharmaceuticals, Inc. give?
- On 2026-08-13: "FY2026 revenue guidance raised to >$145M from >$120M; Adj. EBITDA margin guidance raised to at least 35%."
- When does Eton Pharmaceuticals, Inc. report earnings?
- Eton Pharmaceuticals, Inc.'s next earnings report is expected on 2026-11-05.
Every figure on this page comes from Eton Pharmaceuticals, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.